AR033123A1 - Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores - Google Patents
Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumoresInfo
- Publication number
- AR033123A1 AR033123A1 ARP020101264A ARP020101264A AR033123A1 AR 033123 A1 AR033123 A1 AR 033123A1 AR P020101264 A ARP020101264 A AR P020101264A AR P020101264 A ARP020101264 A AR P020101264A AR 033123 A1 AR033123 A1 AR 033123A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- obtaining
- modified
- antibody
- murine
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 241001529936 Murinae Species 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 abstract 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se relaciona con el campo de la biotecnología y más específicamente con la obtencion de nuevos anticuerpos recombinantes mediante el empleo de la tecnología de ADN recombinante. El objeto de la presente es la obtencion de anticuerpos monoclonales (AcM) menos inmunogénicos y que conserven la afinidad de union al ligando, para su uso terapéutico en humanos. La esencia radica en la obtencion de anticuerpos modificados, cuyas modificaciones se realizan por ingeniería genética sobre secuencias del anticuerpo monoclonal murino P3 (AcM P3), producido por el hibridoma depositado segun el tratado de Budapest bajo el numero ECACC 94113026 y de su anticuerpo monocolonal anti-idiotipo 1E10 (AcMai 1E10), ECACC 97112901, con el objetivo de obtener un anticuerpo modificado con las mismas propiedades de reconocimiento del anticuerpo original y que resulte menos inmunogénico cuando es aplicado a pacientes. Los anticuerpos modificados que se describen son: los quiméricos que contienen los dominios variables de la inmunoglobulina murina y las regiones constantes de la inmunoglobulina humana; y los anticuerpos humanizados que, además de contener las regiones constantes de la inmunoglobulina humana han sido modificados específicamente en la region de los marcos (FRs) murinos y dentro de estos en aquellas zonas que pudieran resultar en un sito antigénico para las células T, de forma tal que hay algunas posiciones de los FRS que son humanas. Además se relaciona con el uso de los anticuerpos modificados para el diagnostico y terapia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2001008420010084A CU23007A1 (es) | 2001-04-06 | 2001-04-06 | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
Publications (1)
Publication Number | Publication Date |
---|---|
AR033123A1 true AR033123A1 (es) | 2003-12-03 |
Family
ID=40291118
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101264A AR033123A1 (es) | 2001-04-06 | 2002-04-05 | Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores |
ARP020101263A AR033122A1 (es) | 2001-04-06 | 2002-04-05 | Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobre-expresan gangliosidos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101263A AR033122A1 (es) | 2001-04-06 | 2002-04-05 | Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobre-expresan gangliosidos |
Country Status (37)
Country | Link |
---|---|
US (3) | US20050069535A1 (es) |
EP (3) | EP1384726B1 (es) |
JP (2) | JP4366080B2 (es) |
KR (3) | KR100863509B1 (es) |
CN (3) | CN101054417B (es) |
AR (2) | AR033123A1 (es) |
AT (3) | ATE477279T1 (es) |
AU (3) | AU2002308348B2 (es) |
BG (2) | BG66293B1 (es) |
BR (3) | BR0208676B1 (es) |
CA (2) | CA2443372C (es) |
CU (1) | CU23007A1 (es) |
CZ (2) | CZ296276B6 (es) |
DE (2) | DE60223547T2 (es) |
DK (2) | DK1384726T3 (es) |
EA (2) | EA006936B1 (es) |
EC (2) | ECSP034788A (es) |
ES (2) | ES2296986T3 (es) |
HK (3) | HK1066818A1 (es) |
HR (2) | HRP20030806B1 (es) |
HU (2) | HU228106B1 (es) |
IL (2) | IL158246A0 (es) |
IS (2) | IS6965A (es) |
MX (2) | MXPA03008739A (es) |
MY (3) | MY145703A (es) |
NO (2) | NO20034437L (es) |
NZ (2) | NZ528598A (es) |
PE (1) | PE20020972A1 (es) |
PL (2) | PL208109B1 (es) |
PT (2) | PT1384726E (es) |
SG (1) | SG161737A1 (es) |
SI (2) | SI1411064T1 (es) |
SK (2) | SK287783B6 (es) |
UA (3) | UA75393C2 (es) |
UY (2) | UY27242A1 (es) |
WO (2) | WO2002081496A2 (es) |
ZA (2) | ZA200307585B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
CN101111260B (zh) * | 2005-02-04 | 2013-03-20 | 萨瓦克公司 | 存活蛋白肽疫苗 |
FI20055398A0 (fi) | 2005-07-08 | 2005-07-08 | Suomen Punainen Risti Veripalv | Menetelmä solupopulaatioiden evaluoimiseksi |
EP2594591B1 (en) * | 2005-08-11 | 2018-06-06 | Arpi Matossian-Rogers | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
JP5415071B2 (ja) * | 2005-08-19 | 2014-02-12 | ワイス・エルエルシー | Gdf−8に対するアンタゴニスト抗体ならびにalsおよびその他のgdf−8関連障害の処置における使用 |
ITFI20060163A1 (it) * | 2006-06-29 | 2006-09-28 | Menarini Internat Operations Luxembourg Sa | Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio |
TWI434855B (zh) | 2006-11-21 | 2014-04-21 | Hoffmann La Roche | 結合物及其在免疫分析中作為參考標準之用途 |
WO2009104649A1 (ja) * | 2008-02-22 | 2009-08-27 | 片山化学工業株式会社 | 合成糖脂質含有リポソーム |
EP2166085A1 (en) | 2008-07-16 | 2010-03-24 | Suomen Punainen Risti Veripalvelu | Divalent modified cells |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
NZ594985A (en) * | 2009-03-10 | 2013-07-26 | Biogen Idec Inc | Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies |
SG174992A1 (en) | 2009-04-01 | 2011-11-28 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
CU23736A1 (es) * | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
WO2011026242A1 (en) * | 2009-09-03 | 2011-03-10 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
WO2012096994A2 (en) * | 2011-01-10 | 2012-07-19 | Emory University | Antibodies directed against influenza |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
EP2641916A1 (en) * | 2012-03-23 | 2013-09-25 | Centre National de la Recherche Scientifique (C.N.R.S) | Novel antibodies anti-sPLA2-IIA and uses thereof |
MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
UA120753C2 (uk) | 2013-12-17 | 2020-02-10 | Дженентек, Інк. | Біспецифічне антитіло до сd3 та cd20 |
JP2017512759A (ja) * | 2014-04-10 | 2017-05-25 | オービーアイ ファーマ インコーポレイテッド | 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途 |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
CA2986928A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Humanized and affinity matured antibodies to fcrh5 and methods of use |
WO2018017864A2 (en) * | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
CA3044664C (en) | 2016-11-30 | 2022-11-22 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2754206B2 (ja) * | 1987-11-17 | 1998-05-20 | メクト株式会社 | α2→3結合を認識するモノクローナル抗体 |
US6051225A (en) * | 1988-10-19 | 2000-04-18 | The Dow Chemical Company | Family of high affinity, modified antibodies for cancer treatment |
EP0586002B1 (en) * | 1992-08-18 | 2000-01-19 | CENTRO de IMMUNOLOGIA MOLECULAR | Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them |
JPH07101999A (ja) * | 1993-10-06 | 1995-04-18 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするdna塩基配列 |
US6063379A (en) * | 1993-12-09 | 2000-05-16 | Centro De Inmunologia Molecular | Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies |
CU22702A1 (es) * | 1997-10-21 | 2001-07-31 | Centro Inmunologia Molecular | Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen |
EP0657471B1 (en) * | 1993-12-09 | 2001-10-24 | Centro de Inmunologia Molecular | Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours |
CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
-
2001
- 2001-04-06 CU CU2001008420010084A patent/CU23007A1/es unknown
-
2002
- 2002-04-05 MY MYPI20081190A patent/MY145703A/en unknown
- 2002-04-05 UY UY27242A patent/UY27242A1/es not_active Application Discontinuation
- 2002-04-05 MY MYPI20021239A patent/MY157372A/en unknown
- 2002-04-05 AR ARP020101264A patent/AR033123A1/es not_active Application Discontinuation
- 2002-04-05 AR ARP020101263A patent/AR033122A1/es unknown
- 2002-04-05 UY UY27243A patent/UY27243A1/es unknown
- 2002-04-05 MY MYPI20021228A patent/MY137078A/en unknown
- 2002-04-08 HU HU0401355A patent/HU228106B1/hu not_active IP Right Cessation
- 2002-04-08 MX MXPA03008739A patent/MXPA03008739A/es active IP Right Grant
- 2002-04-08 JP JP2002580025A patent/JP4366080B2/ja not_active Expired - Fee Related
- 2002-04-08 BR BRPI0208676A patent/BR0208676B1/pt not_active IP Right Cessation
- 2002-04-08 ES ES02759752T patent/ES2296986T3/es not_active Expired - Lifetime
- 2002-04-08 SK SK1216-2003A patent/SK287783B6/sk not_active IP Right Cessation
- 2002-04-08 AT AT06076643T patent/ATE477279T1/de not_active IP Right Cessation
- 2002-04-08 PL PL371937A patent/PL208109B1/pl unknown
- 2002-04-08 KR KR1020037012938A patent/KR100863509B1/ko not_active IP Right Cessation
- 2002-04-08 PT PT02759751T patent/PT1384726E/pt unknown
- 2002-04-08 NZ NZ528598A patent/NZ528598A/en not_active IP Right Cessation
- 2002-04-08 SG SG200506530-5A patent/SG161737A1/en unknown
- 2002-04-08 HU HU0401695A patent/HU228105B1/hu not_active IP Right Cessation
- 2002-04-08 PL PL02371770A patent/PL371770A1/xx not_active Application Discontinuation
- 2002-04-08 CA CA2443372A patent/CA2443372C/en not_active Expired - Fee Related
- 2002-04-08 SI SI200230660T patent/SI1411064T1/sl unknown
- 2002-04-08 CZ CZ20032641A patent/CZ296276B6/cs not_active IP Right Cessation
- 2002-04-08 CZ CZ2003-2668A patent/CZ304424B6/cs not_active IP Right Cessation
- 2002-04-08 EP EP02759751A patent/EP1384726B1/en not_active Expired - Lifetime
- 2002-04-08 JP JP2002579482A patent/JP2004528033A/ja active Pending
- 2002-04-08 AU AU2002308348A patent/AU2002308348B2/en not_active Ceased
- 2002-04-08 DK DK02759751T patent/DK1384726T3/da active
- 2002-04-08 US US10/473,978 patent/US20050069535A1/en not_active Abandoned
- 2002-04-08 DE DE60223547T patent/DE60223547T2/de not_active Expired - Lifetime
- 2002-04-08 KR KR1020037012969A patent/KR100946168B1/ko not_active IP Right Cessation
- 2002-04-08 EP EP06076643A patent/EP1798243B1/en not_active Expired - Lifetime
- 2002-04-08 AT AT02759751T patent/ATE406386T1/de active
- 2002-04-08 WO PCT/CU2002/000003 patent/WO2002081496A2/es active Application Filing
- 2002-04-08 DK DK02759752T patent/DK1411064T3/da active
- 2002-04-08 CN CN2007101021039A patent/CN101054417B/zh not_active Expired - Fee Related
- 2002-04-08 DE DE60228561T patent/DE60228561D1/de not_active Expired - Lifetime
- 2002-04-08 IL IL15824602A patent/IL158246A0/xx unknown
- 2002-04-08 AT AT02759752T patent/ATE378356T1/de active
- 2002-04-08 WO PCT/CU2002/000002 patent/WO2002081661A2/es active IP Right Grant
- 2002-04-08 PE PE2002000283A patent/PE20020972A1/es not_active Application Discontinuation
- 2002-04-08 ES ES02759751T patent/ES2312610T3/es not_active Expired - Lifetime
- 2002-04-08 EP EP02759752A patent/EP1411064B1/en not_active Expired - Lifetime
- 2002-04-08 CA CA2441845A patent/CA2441845C/en not_active Expired - Fee Related
- 2002-04-08 PT PT02759752T patent/PT1411064E/pt unknown
- 2002-04-08 SI SI200230766T patent/SI1384726T1/sl unknown
- 2002-04-08 BR BR0208675-1A patent/BR0208675A/pt not_active IP Right Cessation
- 2002-04-08 US US10/473,977 patent/US20040253233A1/en not_active Abandoned
- 2002-04-08 NZ NZ528599A patent/NZ528599A/en not_active IP Right Cessation
- 2002-04-08 CN CNB028086309A patent/CN100349920C/zh not_active Expired - Fee Related
- 2002-04-08 CN CNB028084330A patent/CN1319991C/zh not_active Expired - Fee Related
- 2002-04-08 EA EA200301097A patent/EA006936B1/ru not_active IP Right Cessation
- 2002-04-08 MX MXPA03008738A patent/MXPA03008738A/es not_active Application Discontinuation
- 2002-04-08 EA EA200301098A patent/EA006310B1/ru not_active IP Right Cessation
- 2002-04-08 AU AU2002308347A patent/AU2002308347B2/en not_active Ceased
- 2002-04-08 SK SK1226-2003A patent/SK287914B6/sk not_active IP Right Cessation
- 2002-04-08 BR BRPI0208675-1A patent/BRPI0208675B1/pt unknown
- 2002-08-04 UA UA2003108989A patent/UA75393C2/uk unknown
- 2002-08-04 UA UA2003108988A patent/UA76745C2/uk unknown
-
2003
- 2003-09-23 IS IS6965A patent/IS6965A/is unknown
- 2003-09-23 IS IS6964A patent/IS2701B/is unknown
- 2003-09-29 ZA ZA200307585A patent/ZA200307585B/en unknown
- 2003-09-30 EC EC2003004788A patent/ECSP034788A/es unknown
- 2003-09-30 EC EC2003004787A patent/ECSP034787A/es unknown
- 2003-10-01 ZA ZA2003/07679A patent/ZA200307679B/en unknown
- 2003-10-02 IL IL158246A patent/IL158246A/en not_active IP Right Cessation
- 2003-10-03 NO NO20034437A patent/NO20034437L/no not_active Application Discontinuation
- 2003-10-03 BG BG108227A patent/BG66293B1/en unknown
- 2003-10-03 NO NO20034436A patent/NO331533B1/no not_active IP Right Cessation
- 2003-10-03 BG BG108228A patent/BG66304B1/bg unknown
- 2003-10-06 HR HR20030806A patent/HRP20030806B1/xx not_active IP Right Cessation
- 2003-10-06 HR HR20030805A patent/HRP20030805B1/xx not_active IP Right Cessation
-
2004
- 2004-12-14 HK HK04109894A patent/HK1066818A1/xx not_active IP Right Cessation
-
2005
- 2005-04-01 HK HK05102752A patent/HK1070080A1/xx not_active IP Right Cessation
- 2005-12-20 UA UAA200512270A patent/UA86768C2/ru unknown
-
2007
- 2007-10-26 AU AU2007231687A patent/AU2007231687B2/en not_active Expired - Fee Related
- 2007-12-31 HK HK07114311.6A patent/HK1109160A1/xx not_active IP Right Cessation
-
2008
- 2008-08-07 KR KR1020087019420A patent/KR100919617B1/ko not_active IP Right Cessation
-
2009
- 2009-03-19 US US12/407,046 patent/US8758753B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR033123A1 (es) | Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores | |
DE69605181T3 (de) | Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern | |
KR927003816A (ko) | Cd3에 대한 항체 | |
RU2425841C2 (ru) | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 | |
RU96115107A (ru) | "очеловеченные" антитела и их использование | |
HUP0101160A2 (hu) | Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására | |
MX9201016A (es) | Anticuerpos monoclonales humanizados y quimericos | |
ATE316137T1 (de) | Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor | |
KR920702425A (ko) | Cdr 이식된 항-cea 항체 및 그의 제조 | |
FI973120A (fi) | Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa | |
DE69529649D1 (de) | Anti-egfr einkettige fvs und anti-egfr antikoerper | |
RU2001104893A (ru) | Гибридное антитело IgG человека/грызуна против CD3 и способы его конструирования | |
DE69327620D1 (de) | Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen | |
PT99934A (pt) | Processo para a producao de um anticorpo anti-htnf alfa recombinante ou humanizado | |
CN109311983A (zh) | 人源化抗clever-1抗体及其用途 | |
ATE370235T1 (de) | Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden | |
DE10210427A1 (de) | Humaner monoklonaler Antikörper | |
EP0213581A2 (de) | Monoklonale Antikörper gegen tumorassoziierte Glykoproteine, Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
KR100280948B1 (ko) | 모노클로날항-강글리오사이드 항체, 이의 제조방법 및 이를 함유하는 종양진단제 | |
KR890016165A (ko) | 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도 | |
AR026463A1 (es) | ANTICUERPOS Y FRAGMENTOS Fv QUE RECONOCEN EL ANTIGENO ior C2 | |
Kusakabe et al. | Accumulation enhancement of human monoclonal antibody HB4C5 to lung tumor xenografts by N-deglycosylation | |
CY1107163T1 (el) | Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων | |
Hashizume et al. | Clinical applications of human monoclonal antibodies | |
DK182188A (da) | Humant tumorassocieret antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed, e.g., due to non-payment of fee |